Search results
Rupert Davies - Alpine Immune Sciences, Inc. | LinkedIn. Seattle, Washington, United States. 529 followers 500+ connections. View mutual connections with Rupert. Welcome back. Alpine...
- 500+
- 529
- Alpine Immune Sciences, Inc.
- Seattle, Washington, United States
Rupert Davies rupert.davies@alpineimmunesciences.com Alpine Immune Sciences, Inc. R and D Seattle
See Free Details & Reputation Profile for Rupert Davies (50) in Seattle, WA. Includes free contact info & photos & court records.
Rupert Davies is an Executive Director, Translational Medicine at Alpine Immune Sciences based in Seattle, Washington. Previously, Rupert was a Se nior Director, Translational Sciences At Zymeworks Inc. at Zymeworks and also held positions at Amgen, Implicit Bioscience, Allomodus, University of Washington, University of Utah.
Nov 2, 2023 · Catherine Broome, David J Kuter, Keith R. McCrae, Rupert Davies, Amanda Enstrom, Allison Chunyk, Heather Thomas, Allison Naumovski, Steven R. Lentz; Initial Report of Povetacicept, an Enhanced Dual BAFF/APRIL Antagonist, in Autoimmune Cytopenias: The RUBY-4 Study. Blood 2023; 142 (Supplement 1): 5520. doi: https://doi.org/10.1182/blood-2023-179305
Nov 15, 2022 · A Randomized, Placebo-Controlled, Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Autoimmune Cytopenias. Stacey R. Dillon, Rupert Davies,
Aug 8, 2023 · Aims: To evaluate povetacicept in a preclinical model of autoimmune cytopenia (AIHA) and to assess its initial safety, pharmacokinetics (PK), and pharmacodynamics (PD) in adult healthy volunteers (HV) in preparation for clinical trials in patients with autoimmune cytopenias.
